ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements with these filters
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma announced that the USFDA completed a routine GMP inspection of its Visakhapatnam facility with zero Form 483 observations.
Gland Pharma Limited held its 48th Annual General Meeting on August 25, 2026. The company provided its proceedings and the Chairman's speech.
Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.
Gland Pharma Limited has appointed Mr. Deepak Sapra as the new Chief Executive Officer, effective from November 16, 2026.
Gland Pharma reports a strong start to FY27, driven by CDMO and B2B growth, though currency shifts significantly impacted the bottom line compared to the previous quarter.
Gland Pharma reported Q1FY27 revenue of ₹18,003 Mn (20% YoY) with PAT of ₹3,170 Mn (47% YoY). Growth was driven by CDMO product launches and B2B volume expansion in US and Europe.
Gland Pharma reported Q1 FY27 revenue of ₹1,800.3 Cr and PAT of ₹317 Cr, with 20% and 47% year-on-year growth respectively.
Gland Pharma Ltd reported revenue from operations of ₹1,800 Cr (+19.6% YoY) and net profit of ₹317 Cr (+47.1% YoY) for Q1 FY27.
Gland Pharma signed a strategic CDMO manufacturing agreement with a global pharmaceutical company. The partnership has an annualized revenue potential of approximately ₹855-950 Crore.
Gland Pharma signed a manufacturing and supply agreement with a global partner for sterile injectables. The partnership targets revenue from 2029 with 55 initial SKUs.
Gland Pharma signed a strategic manufacturing agreement with a global pharmaceutical company. The partnership has an annualized revenue potential of approximately ₹902.5 Crore.
Gland Pharma announced a long-term strategic CDMO partnership with Neuland Laboratories to expand its sterile API manufacturing infrastructure at its Visakhapatnam facility.
Gland Pharma Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, as per SEBI regulations.
Gland Pharma has issued a notice for its 48th Annual General Meeting to be held on August 25, 2026. The meeting agenda includes dividend declaration and director reappointments.
Gland Pharma Limited announced the grant of 16,790 employee stock options to 3 employees under the Gland Pharma Employee Stock Option Scheme 2025.
Gland Pharma received USFDA approval for Sugammadex Injection single-dose vials. The product has been successfully launched via its marketing partner.
Gland Pharma Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone and consolidated financial results.
Gland Pharma shareholders approved the reappointment of Udo Jahannes Vetter and the appointment of William Robert Keller as Independent Directors for five-year terms.
Gland Pharma Limited announced the results of the Postal Ballot, where all proposed resolutions regarding the appointment and remuneration of Independent Directors were passed.
Gland Pharma submitted its quarterly shareholding pattern for the period ending June 30, 2026. This is a routine regulatory disclosure.
Gland Pharma received a ₹7.06 Crore demand and penalty notice from Customs Authorities. The company plans to appeal, citing no material financial impact.
Gland Pharma received a Rs. 7.06 Crore demand from Customs Authority, including IGST and penalties. The company intends to appeal against the order.
Mirae Asset Mutual Fund sold a 0.18% stake in Gland Pharma via open market. Its holding decreased from 5.17% to 4.98%.